Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Immunotherapy by Nivolumab for HIV+ Patients (CHIVA2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03304093
Recruitment Status : Active, not recruiting
First Posted : October 6, 2017
Last Update Posted : February 10, 2021
ANRS, Emerging Infectious Diseases
Information provided by (Responsible Party):
Intergroupe Francophone de Cancerologie Thoracique

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : March 2021
Estimated Study Completion Date : December 2021